Repligen "market outperform," target price raised

04/12/07 - Rodman & Renshaw

NEW YORK, April 12 (newratings.com) - Analysts at Rodman & Renshaw reiterate their "market outperform" rating on Repligen Corp (RGEN). The 12-month target price has been raised from $5 to $6.

In a research note published this morning, the analysts mention that the company is likely to gain customers for Protein A and announce results of the ongoing Phase II trials over the next four months. Repligen is inlicensing unique compounds for the treatment of orphan neurological disease Freidreich’s Ataxia (FA), the analysts say. The company is progressing with its study of human secretin for pancreatic imaging, Rodman & Renshaw adds.